Pharma BD Deal Intelligence
Allergan's $621M bet on two Phase 2 Vitae Pharmaceuticals dermatology assets was a bust—the atopic dermatitis LXRβ agonist failed proof-of-concept within months of close, and the lead RORγt psoriasis candidate flopped on safety in 2018, forcing a $522M impairment and killing both programs before any product reached market.
A $621M bet on two Phase 2 dermatology assets that both flopped — Allergan wrote off $522M (84% of deal value) within 18 months of close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Vitae traded at around $8 a share before the announcement; Allergan's $21-a-share cash offer represents a premium of roughly 160% as it further expands its…
Pharmaceutical Technology reported the $639M deal at $21/share with neutral framing — noting both lead assets were Phase 2 stage and the platform value rested…
Factual trade coverage reproducing executive framing: both the VTP-43742 and VTP-38543 programs 'offer the potential for highly differentiated mechanisms of…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Allergan acquired Vitae Pharmaceuticals for $21.00/share, ~$639M total. Adds first-in-class oral RORgammaT inhibitor VTP-43742 (psoriasis) and topical LXRbeta agonist VTP-38543 (atopic dermatitis) plus Vitae's Contour drug discovery platform to Allergan's medical dermatology pipeline. Closed October 25, 2016.
A $621M bet on two Phase 2 dermatology assets that both flopped — Allergan wrote off $522M (84% of deal value) within 18 months of close.
Assessment window: 5yr post-close.
Plaque psoriasis is a chronic immune-mediated skin disease characterized by scaly erythematous plaques driven by IL-23/IL-17 axis dysregulation, affecting roughly 7.5 million US adults. Atopic dermatitis is a chronic relapsing inflammatory dermatosis affecting roughly 1 in 10 Americans across all ages and up to 1 in 5 children, marked by intense pruritus, barrier dysfunction, and Th2-skewed inflammation. Both conditions saw a wave of biologic innovation in the mid-2010s that reset patient expectations.
When Allergan announced the $639M Vitae deal (Sept 2016), the psoriasis market was being reshaped by IL-17 biologics — Novartis's Cosentyx (secukinumab, 2015), Lilly's Taltz (ixekizumab, 2016), and Valeant's Siliq (brodalumab, 2017) — alongside the IL-23 class led by J&J's Tremfya (guselkumab, 2017) and AbbVie's Skyrizi (later). VTP-43742 was positioned as a first-in-class oral RORgammaT inhibitor that suppresses IL-17 production upstream, offering convenience advantages over injectable biologics. VTP-38543 was a topical LXRbeta agonist for atopic dermatitis competing in a market about to be redefined by Sanofi/Regeneron's Dupixent (dupilumab, March 2017). Allergan paid $21/share (~$639M) on the strength of these two assets plus Vitae's Contour structure-based discovery platform. Outcome was poor: in mid-2017, VTP-43742 was discontinued after Phase 2b in psoriasis fell short of efficacy and tolerability bars (Leerink listed it among Allergan's 'didn't like' items), and the broader Vitae dermatology thesis underperformed prior to Allergan's own AbbVie acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Vitae Pharmaceuticals, Inc. (this deal) | 2016 | $639M | 13 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
← Browse all deals · How we score deals
More: 2016 deals · Allergan plc deals · Dermatology deals